Orlistat Enhances Warfarin Effect
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To report a case of increased international normalized ratio (INR) associated with the addition of orlistat to the drug regimen of a patient receiving warfarin therapy. CASE SUMMARY: A 66-year-old white man with a history of chronic atrial fibrillation (treated with a stable dose of warfarin), hypertension, and diet-controlled type 2 diabetes mellitus was started on orlistat for weight reduction. An increased INR was reported after the introduction of orlistat; there had been no other recent changes to medication or medical conditions. Warfarin was withheld and the dose reduced to allow INR control to be reestablished. According to the Naranjo probability scale, this reaction was probable. DISCUSSION: Control of the INR within therapeutic limits is always a challenge. Dietary intake of vitamin K, intercurrent illness, concomitant medication, herbal remedies, and other factors can interfere with warfarin dosing. Orlistat use may be associated with patient alteration of diet to compensate for adverse effects or other mechanisms by which orlistat alters warfarin control, including direct effect on absorption of vitamin K. CONCLUSIONS: The introduction of chronic dosing of orlistat may reduce the absorption of fat-soluble vitamins, including vitamin K, with the result that a lower dose of warfarin may be required. This may be due in part to change to a lower fat diet with decreased amounts of vitamin K. It may also be due to an effect on vitamin K absorption. Caution should be exercised when these 2 drugs are used concurrently.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A method for estimating the probability of adverse drug reactions
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1981.154 · Cited by 11,914
Cited by
Systematic overview of warfarin and its drug and food interactions
Holbrook, A. M. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.10.1095 · Cited by 1,160
Drug treatments for obesity: orlistat, sibutramine, and rimonabant
Padwal, R. S., & Majumdar, S. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60033-6 · Cited by 753
Orlistat-Associated Adverse Effects and Drug Interactions: A Critical Review
Filippatos, T. D., Derdemezis, C. S., Gazi, I. F., Nakou, E. S., Mikhailidis, D. P., & Elisaf, M. S. (2008) · Drug Safety · doi:10.2165/00002018-200831010-00005 · Cited by 434
Mladěnka, P., Macáková, K., Kujovská Krčmová, L., Javorská, L., Mrštná, K., Carazo, A., Protti, M., Remião, F., Nováková, L., & collaborators, T. O. R. A. (2022) · Nutrition Reviews · doi:10.1093/nutrit/nuab061 · Cited by 262
Derosa, G., Cicero, A. F. G., Murdolo, G., Piccinni, M. N., Fogari, E., Bertone, G., Ciccarelli, L., & Fogari, R. (2005) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00372.x · Cited by 67
Epidemiology of Obesity and Pharmacologic Treatment Options
Shettar, V., Patel, S., & Kidambi, S. (2017) · Nutrition in Clinical Practice · doi:10.1177/0884533617713189 · Cited by 26
“A multivitamin added at night (separately from the medication) is recommended to help prevent deficiencies in fat-soluble vitamins.(113) Because of the potential for decreased fat-soluble vitamin absorption, warfarin dosing may need to be lowered because of decreased vitamin K absorption.”
BackgroundPharmacological Treatment of Obesity in Older Adults
Žižka, O., Haluzík, M., & Jude, E. B. (2024) · Drugs & Aging · doi:10.1007/s40266-024-01150-9 · Cited by 23
Metadata
- Authors
- MacWalter, R. S., Fraser, H. W., & Armstrong, K. M.
- Venue
- Annals of Pharmacotherapy
- Publisher
- SAGE Publications
- Published
- 2003-04
- Volume
- 37
- Issue
- 4
- Pages
- 510-512
- ISSN
- 0012-6578 (ISSN-L)
- 1060-0280
- 1542-6270
- OpenAlex
- W2144724562
- Cited by
- 58
- References
- 1
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.